Tips and tricks for RNAi success - make sure to include necessary controls in your transfections!
Review of selected articles showing the broad applicability of the HAP1 cell line between 2011 and 2019.
Choosing the right cell-based screen from the plethora of options available can quickly become a complicated decision process. Here, we review two of the major options: cell panel and functional genomic screening.
The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.
Learn how reference standards play a key role in increasing and confirming the accuracy of diagnostic testing, thus bringing us closer to precision medicine and targeted therapy.
HAP1 cell lines are a popular choice to validate a range of research experiments, but if you've never used them before, you want to be sure they are right for you.
Liquid biopsy is fast becoming a realistic clinical diagnostic tool, capable of profiling the molecular makeup of a tumor that aids in choosing the right drug and in monitoring treatment response. Studies for its use in early cancer detection are already underway with promising results.
After all the hard work of editing your cell line, you want to have confidence in your new research model. So, how do you verify your cell line is what you expect it to be? Could a heterogeneous cell population be obscuring your editing effects? Is observed phenotype being caused by the targeted gene edit, or unintended off-target effects? Here we discus ways to add supporting data to validate your gene-engineering projects.
CRISPR-edited cell lines are a useful tool to validate your antibodies before you start an experiment. They ensure you are using high quality reagents, so you can be confident in your results. Here we explain how you can use our edited cell lines for validation, the challenges to be aware of and how we can help you overcome them.
Acute Myeloid Leukaemia (AML) is a group of blood cancer malignancies that originate from the uncontrolled proliferation of blast cells in the bone marrow and circulating blood1. AML is a relatively rare disorder - representing less than 1% of total cancer cases.